

APPENDIX 3Y- JONATHAN DAVEY

Sydney, 26 June 2025 – Tyro Payments Limited (Tyro) has today released an Appendix 3Y relating to a change of Director's Interest of Jonathan Davey. The Appendix 3Y is attached to this announcement.

For more information, please contact:

Media:

Gemma Garkut
+61 422 040 559
media@tyro.com

Investors:

Martyn Adlam
+61 452 112 621
investorrelations@tyro.com

Pursuant to Listing Rule 15.5, Tyro confirms this document has been authorised for release by the CEO & Managing Director.

About Tyro

In 2003, Tyro set out to make payments the easiest part of doing business. Today, we're still into business big time, powering more than 73,000 merchants across Australia with in-store, online and on-the-go payment solutions. Working with more than 700 partners, we create seamless payment experiences for hospitality, retail, services and health providers, with integrated banking and lending solutions designed to help unlock the potential of every business. For more information, visit tyro.com.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity.	Tyro Payments Limited
ABN	49 103 575 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jonathan Charles Davey
Date of last notice	17 June 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	NA
Date of change	19 June 2025

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p><u>Direct interests:</u></p> <ul style="list-style-type: none"> • 36,082 fully paid ordinary shares. • 297,619 Medipass Service Rights convertible into fully paid ordinary shares. • 297,619 Medipass Performance Rights convertible into fully paid ordinary shares. • 25,314 FY22 Rights convertible into fully paid ordinary shares. • 159,576 FY23 STI Equity Rights convertible into fully paid ordinary shares. • 159,577 FY23 STI Equity Rights convertible into fully paid ordinary shares. • 1,282,051 FY23 LTI Performance Rights convertible into fully paid ordinary shares. • 1,086,956 FY24 LTI Performance Rights convertible into fully paid ordinary shares. • 173,581 FY24 STI Equity Rights convertible into fully paid ordinary shares. <p><u>Indirect interests:</u></p> <ul style="list-style-type: none"> • 179,381 Ordinary Shares held in escrow in an employee share trust subject to the repayment of a loan granted to the employee.
Class	TYRAA- Performance Rights
Number acquired	1,497,033 FY25 LTI Performance Rights
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	NA

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p><u>Direct interests:</u></p> <ul style="list-style-type: none"> • 36,082 fully paid ordinary shares. • 297,619 Medipass Service Rights convertible into fully paid ordinary shares. • 297,619 Medipass Performance Rights convertible into fully paid ordinary shares. • 25,314 FY22 Rights convertible into fully paid ordinary shares. • 159,576 FY23 STI Equity Rights convertible into fully paid ordinary shares. • 159,577 FY23 STI Equity Rights convertible into fully paid ordinary shares. • 1,282,051 FY23 LTI Performance Rights convertible into fully paid ordinary shares. • 1,086,956 FY24 LTI Performance Rights convertible into fully paid ordinary shares. • 173,581 FY24 STI Equity Rights convertible into fully paid ordinary shares. • 1,497,033 FY25 LTI Performance Rights convertible into fully paid ordinary shares. <p><u>Indirect interests:</u></p> <ul style="list-style-type: none"> • 179,381 Ordinary Shares held in escrow in an employee share trust subject to the repayment of a loan granted to the employee.
<p>Nature of change</p> <p>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of Performance Rights under the FY25 LTI plan, as approved by Shareholders at the 2024 AGM.</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	<p>Tyro Health Pty Ltd (formerly named Medipass Solutions Pty Ltd), a wholly owned subsidiary of Tyro Payments Ltd agreed to loan Jonathan Davey an amount of \$333,824.81 (Loan) to acquire 179,381 shares in Tyro Payments Limited.</p> <p>These shares are held by Pacific Custodians Pty Ltd (as trustee for Medipass Employee Share Trust)</p>
Nature of interest	<p>Party to loan agreement</p>
Name of registered holder (if issued securities)	<p>Pacific Custodians Pty Limited (as trustee for Medipass Employee Share Trust)</p>

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Date of change	19 June 2025
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	179,381 ordinary shares
Interest acquired	NA
Interest disposed	NA
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	NA
Interest after change	NA

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	NA
If prior written clearance was provided, on what date was this provided?	NA

⁺ See chapter 19 for defined terms.